Bruker Announces Strategic Minority Investment in NovAliX
Bruker (Nasdaq: BRKR) has announced a strategic minority investment in NovAliX, a preclinical Contract Research Organization (CRO) specializing in drug discovery services. The investment aims to accelerate NovAliX's growth and expansion in Europe and the United States. The partnership will focus on developing novel drug discovery technologies and methods, leveraging biophysical methods, particularly NMR.
Key collaboration areas include:
- Ultra-high field NMR for structural and binding investigations
- NMR-powered medicinal chemistry and mechanism of action research
- X-ray crystallography for structure-guided drug discovery
- High-sensitivity SPR for kinetics and binding studies
- Mass spectrometry for proteomics and multiomics
- Single cell and spatial biology tools for drug discovery insights
The partnership aims to enable new paradigms in drug discovery, accelerate development of advanced biophysical methods, and support the discovery of new and better medicines.
Bruker (Nasdaq: BRKR) ha annunciato un investimento strategico in minoranza in NovAliX, un'Organizzazione di Ricerca su Contratto (CRO) preclinica specializzata nei servizi di scoperta di farmaci. L'investimento mira ad accelerare la crescita e l'espansione di NovAliX in Europa e negli Stati Uniti. La partnership si concentrerà sullo sviluppo di nuove tecnologie e metodi per la scoperta di farmaci, sfruttando metodi biofisici, in particolare la NMR.
Le principali aree di collaborazione includono:
- NMR a ultra-alta campo per indagini strutturali e di legame
- Chimica medicinale e ricerca sul meccanismo d'azione potenziate da NMR
- Cristallografia a raggi X per la scoperta di farmaci guidata dalla struttura
- SPR ad alta sensibilità per studi di cinetica e legame
- Spettrometria di massa per proteomica e multiomica
- Strumenti di biologia cellulare singola e spaziale per approfondimenti sulla scoperta di farmaci
La partnership mira a consentire nuovi paradigmi nella scoperta di farmaci, accelerare lo sviluppo di metodi biofisici avanzati e supportare la scoperta di nuovi e migliori medicinali.
Bruker (Nasdaq: BRKR) ha anunciado una inversión estratégica minoritaria en NovAliX, una Organización de Investigación por Contrato (CRO) preclínica especializada en servicios de descubrimiento de fármacos. La inversión tiene como objetivo acelerar el crecimiento y la expansión de NovAliX en Europa y Estados Unidos. La asociación se centrará en el desarrollo de nuevas tecnologías y métodos para el descubrimiento de fármacos, aprovechando métodos biofísicos, particularmente la NMR.
Las principales áreas de colaboración incluyen:
- NMR de ultra alta campo para investigaciones estructurales y de unión
- Química medicinal y investigación del mecanismo de acción potenciadas por NMR
- Cristalografía de rayos X para el descubrimiento de fármacos guiado por la estructura
- SPR de alta sensibilidad para estudios de cinética y unión
- Espectrometría de masas para proteómica y multiómica
- Herramientas de biología de célula única y espacial para obtener información sobre el descubrimiento de fármacos
La asociación tiene como objetivo habilitar nuevos paradigmas en el descubrimiento de fármacos, acelerar el desarrollo de métodos biofísicos avanzados y apoyar el descubrimiento de nuevos y mejores medicamentos.
Bruker (Nasdaq: BRKR)는 약물 발견 서비스에 특화된 전임상 계약 연구 조직 (CRO)인 NovAliX에 대한 전략적 지분 투자를 발표했습니다. 이 투자의 목적은 NovAliX의 유럽 및 미국 내 성장과 확장을 가속화하는 것입니다. 파트너십은 NMR을 특히 활용하는 생물물리학적 방법을 통해 새로운 약물 발견 기술과 방법을 개발하는 데 집중할 것입니다.
주요 협력 분야는 다음과 같습니다:
- 구조 및 결합 조사를 위한 초고자기장 NMR
- NMR을 통한 약리학 및 작용 메커니즘 연구
- 구조 기반 약물 발견을 위한 X선 결정학
- 동역학 및 결합 연구를 위한 고감도 SPR
- 단백질체 및 다중 오믹스 분석을 위한 질량 분석법
- 약물 발견 통찰을 위한 단일 세포 및 공간 생물학 도구
이 파트너십은 약물 발견에 대한 새로운 패러다임을 가능하게 하고, advanced 생물물리학적 방법 개발을 가속화하며, 새로운 및 더 나은 약물 발견을 지원하는 것을 목표로 합니다.
Bruker (Nasdaq: BRKR) a annoncé un investissement stratégique minoritaire dans NovAliX, une Organisation de Recherche Contractuelle (CRO) préclinique spécialisée dans les services de découverte de médicaments. Cet investissement vise à accélérer la croissance et l'expansion de NovAliX en Europe et aux États-Unis. Le partenariat se concentrera sur le développement de nouvelles technologies et méthodes de découverte de médicaments, en s'appuyant sur des méthodes biophysiques, en particulier la RMN.
Les principales zones de collaboration comprennent :
- RMN à ultra-haut champ pour des investigations structurales et de liaison
- Chimie médicinale et recherche sur le mécanisme d'action soutenues par la RMN
- Cristallographie aux rayons X pour la découverte de médicaments guidée par la structure
- SPR haute sensibilité pour les études cinétiques et de liaison
- Spectrométrie de masse pour la protéomique et les multiomics
- Outils de biologie unicellulaire et spatiale pour des aperçus sur la découverte de médicaments
Le partenariat vise à permettre de nouveaux paradigmes dans la découverte de médicaments, à accélérer le développement de méthodes biophysiques avancées et à soutenir la découverte de nouveaux et meilleurs médicaments.
Bruker (Nasdaq: BRKR) hat eine strategische Minderheitsinvestition in NovAliX, eine präklinische Vertragsforschungsorganisation (CRO), die auf Dienstleistungen zur Arzneimittelentdeckung spezialisiert ist, angekündigt. Das Investment zielt darauf ab, das Wachstum und die Expansion von NovAliX in Europa und den Vereinigten Staaten zu beschleunigen. Die Partnerschaft wird sich auf die Entwicklung neuer Technologien und Methoden zur Arzneimittelentdeckung konzentrieren und dabei biophysikalische Methoden, insbesondere NMR, nutzen.
Wichtige Kooperationsbereiche sind:
- Ultra-hochfeld NMR für strukturelle und Bindungsuntersuchungen
- NMR-gestützte Arzneimittelchemie und Wirkmechanismusforschung
- Röntgenkristallographie für die strukturbasierte Arzneimittelentdeckung
- Hochsensitives SPR für Kinetik- und Bindungsstudien
- Massen spektrometrie für Proteomik und Multiomics
- Tools der Einzelzell- und räumlichen Biologie für Einblicke in die Arzneimittelentdeckung
Die Partnerschaft zielt darauf ab, neue Paradigmen in der Arzneimittelentdeckung zu ermöglichen, die Entwicklung fortgeschrittener biophysikalischer Methoden zu beschleunigen und die Entdeckung neuer und besserer Arzneimittel zu unterstützen.
- Strategic investment to accelerate NovAliX's growth and expansion in Europe and the US
- Collaboration on developing novel drug discovery technologies and methods
- Access to Bruker's advanced biophysical characterization methods for NovAliX
- Potential for accelerated drug discovery and development of new medicines
- Joint innovation activities planned through the Biophysics Institute for Biomedical Research (IBRB)
- None.
Insights
Bruker's strategic minority investment in NovAliX is a positive move for both companies. While financial details weren't disclosed, this partnership has significant potential:
- Expands Bruker's reach in the drug discovery market, potentially boosting future revenues
- Provides NovAliX with access to Bruker's advanced technologies, enhancing their service offerings
- Creates synergies in R&D, potentially leading to innovative drug discovery methods
NovAliX's substantial revenue from biopharma collaborations and its expansion into the U.S. and Japan markets indicate strong growth potential. With 430 employees across multiple sites, NovAliX has the scale to capitalize on this partnership, potentially driving value for Bruker's investment.
This partnership is a strategic move in the evolving drug discovery landscape. Key points:
- Combines Bruker's advanced analytical technologies with NovAliX's drug discovery expertise
- Focus on biophysical methods, particularly NMR, could accelerate drug development timelines
- Collaboration on novel areas like condensate biology and intrinsically disordered proteins addresses cutting-edge research needs
The planned joint activities at the upcoming Biophysics Institute for Biomedical Research (IBRB) in Strasbourg could become a hub for innovation in biophysics and drug discovery. This ecosystem approach, involving biotechs and academic groups, has the potential to drive significant advancements in the field.
This partnership positions both companies favorably in the competitive drug discovery market:
- Addresses growing demand for advanced biophysical methods in drug discovery
- Expands NovAliX's capabilities, potentially increasing market share in the CRO space
- Strengthens Bruker's position in providing tools and solutions to biopharma companies
The collaboration's focus on emerging areas like oligonucleotides and peptides aligns with current market trends. NovAliX's expansion into the U.S. and Japan markets, coupled with Bruker's global presence, creates opportunities for international growth. The partnership's emphasis on predicting drug discovery failures earlier could lead to significant cost savings for pharmaceutical companies, making their combined offerings highly attractive.
- NovAliX is a drug discovery focused CRO with award-winning chemistry teams and one of the world’s most comprehensive biophysics platforms.
- Bruker and NovAliX intend to collaborate on enabling new paradigms in drug discovery, leveraging advanced biophysical methods, and NMR in particular, to structural, binding and functional characterization.
NovAliX leadership team Stephan Jenn, Christophe Dubost, and Denis Zeyer (left to right)(Photo: Business Wire)
Bruker and NovAliX collaborate strategically to develop novel drug discovery technologies and methods, with the goal of enabling new paradigms in leveraging biophysical methods for drug discovery. The companies will partner on advancing functional structural biology, biophysical methods for characterizing molecular dynamics and interactions, biocondensates and aggregation, drug candidate binding, therapeutic mechanisms of action (MoA), and elucidating potential off-target effects.
The overarching objectives are to discover new or improved targets, as well as new drug modalities or optimized drug candidates, and to predict drug discovery failures earlier. NovAliX will benefit from Bruker’s unique technologies in innovative high-end biophysical characterization methods, particularly NMR, but also leveraging biosensors, mass spectrometry, single-cell and spatial biology tools, to advance NovAliX services for discovery and development of new medicines even faster.
NovAliX excels in drug discovery, combining biophysics, medicinal chemistry, and pharmacology, and is home to award-winning scientists who have invented drugs that are benefiting patients today. Their advanced biophysics platform supports drug discovery from target assessment to lead optimization. NovAliX partnerships, e.g., with the Max Planck Institute in Cryo-EM, or on a unique DNA-Encoded Library (DEL) platform, highlight their commitment to advancing drug discovery through technology and strategic alliances.
Bruker’s partnership with NovAliX will enable both companies to accelerate the development, incubation, deployment and support for advanced biophysical methods, leveraging Bruker’s leading post-genomic solutions competencies, combined with NovAliX’s expert services and innovation.
Anticipated areas of joint innovation in drug discovery methods include, for example:
- Ultra-high field NMR functional structural and binding investigations on protein and RNA structures and complexes, as well as on novel therapeutic peptides and oligonucleotides
- NMR-powered medicinal chemistry, structure-activity relationships (SAR) and MoA research
- Biologics and new drug modalities higher-order structure confirmation, similarity assessment and QC by NMR
- Unique NMR studies of intrinsically disordered proteins or regions (IDPs/IDRs) for condensate biology in drug discovery and condensate cell biology studies
- X-ray crystallography for structure-guided drug discovery
- High sensitivity, high-throughput SPR for kinetics, affinity, and binding studies
- High-performance MS for proteomics, multiomics, glycobiology, native MS and proteoforms
- Single cell and spatial biology tools for cell and tissue heterogeneity insights for drug discovery
Stephan Jenn, President and Co-founder of NovAliX, commented: “This partnership with Bruker will fortify our leadership in biophysics and drug discovery. Leveraging Bruker’s state-of-the-art analytical technologies and expertise, we can offer advanced biophysical methods to our clients. This collaboration promises to drive significant advancements in drug discovery, leading to new and effective treatments for patients globally.”
“Together with the talented and very experienced scientific team of NovAliX, we aspire to offer cutting-edge biophycial tools and solutions, such as ultra-high field NMR for oligonucleotides and peptides to biopharma and biotech companies,” added Dr. Falko Busse, the President of the Bruker BioSpin Group. “This partnership will help us gain further insights and advance our mission to support the discovery of new and better medicines with our enabling and differentiated life-science research and biopharma QC solutions, in partnership with NovAliX.”
Looking ahead, Bruker and NovAliX also plan to conduct joint innovation activities through the Biophysics Institute for Biomedical Research (IBRB) in
Financial details of the investment were not disclosed. NovAliX achieved substantial revenue from its collaborations with biopharma customers and drug-discovery partners, predominantly in
About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240807340165/en/
Media:
Markus Ziegler
Sr. Director and Head of Group Marketing
Bruker BioSpin
T: +49 172 3733531
E: pr@bruker.com
Investor:
Joe Kostka
Associate Director, Investor Relations
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com
Source: Bruker Corporation
FAQ
What is the purpose of Bruker's investment in NovAliX?
How will the Bruker-NovAliX partnership impact drug discovery?
What are some key areas of collaboration between Bruker (BRKR) and NovAliX?
How many employees does NovAliX have and where are they located?
